Tebentafusp, a T-cell receptor–bispecific molecule that targets glycoprotein 100 and CD3, is approved for adult patients who are positive for HLA-A*02:01 and have unresectable or metastatic uveal ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window MADRID -- The significant survival benefit with the bispecific ...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 4 April 2022) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company ...

MADRID — The positive effect of the bispecific fusion protein tebentafusp on the overall survival of patients with uveal melanoma in the IMCgp100-202 study lasted through at least 36 months of ...

Please provide your email address to receive an email when new articles are posted on . Tebentafusp significantly prolonged OS compared with immune checkpoint inhibitors and other standard therapies ...

An international, open-label trial demonstrated the overall survival benefits of administering tebentafusp to HLA-A*02:01-positive patients with metastatic uveal melanoma. A recent phase 3 trial ...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 6 June 2022) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company ...

OXFORDSHIRE, England & CONSHOHOCKEN, Pa. & ROCKVILLE, Md.--(BUSINESS WIRE)--Immunocore Limited, a leading T cell receptor (TCR) biotechnology company, will present new mechanism of action data in ...

There is a simple discount patient access scheme for tebentafusp. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Patients with inoperable or metastatic uveal melanoma survive longer with the new therapy than with another treatment of physician's choice Institute for Quality and Efficiency in Health Care ...